Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Best Pract Res Clin Haematol. 2010 Jun;23(2):291-303. doi: 10.1016/j.beha.2010.04.001.
Regenerative medicine is the process of creating functional tissue with the aid of stem cells, to repair loss of organ function. Possible targets for regenerative medicine include orthopaedic, cardiac, hepatic, pancreatic and central nervous system (CNS) applications. Umbilical cord blood (CB) has established itself as a legitimate source for haematopoietic stem cell transplantation. It is also considered an accessible and less immunogenic source for mesenchymal, unrestricted somatic and for other stem cells with pluri/multipotent properties. The latter are capable of differentiating into a wide variety of cell types including bone, cartilage, cardiomyocytes and neural. They also possess protective abilities that may contribute to tissue repair even if in vitro differentiation is excluded. In view of the absence of treatment for many devastating diseases, the elucidation of non-haematopoietic applications for CB will facilitate the development of pioneering relevant cell therapy approaches. This review focusses on current studies using human CB-derived cells for regenerative medicine.
再生医学是一种利用干细胞创造功能性组织的过程,用于修复器官功能的丧失。再生医学的可能目标包括骨科、心脏、肝脏、胰腺和中枢神经系统 (CNS) 应用。脐带血 (CB) 已被确立为造血干细胞移植的合法来源。它也被认为是间充质、无限制体和具有多能/多潜能特性的其他干细胞的可及和免疫原性较低的来源。后者能够分化为多种细胞类型,包括骨、软骨、心肌细胞和神经。它们还具有保护能力,即使体外分化被排除,也可能有助于组织修复。鉴于许多毁灭性疾病尚无治疗方法,阐明 CB 的非造血应用将促进开创性相关细胞治疗方法的发展。这篇综述重点介绍了目前使用人 CB 衍生细胞进行再生医学的研究。